Case Note & Summary
The dispute arose from appeals filed by the Union of India against a judgment of the Delhi High Court regarding the price fixation of Doxofylline formulations. The High Court had set aside notifications issued by the government that fixed prices for Doxofylline, ruling that it was not a bulk drug as defined under the Drugs (Prices Control) Order, 1995 (DPCO, 1995). The appellants contended that Doxofylline is a derivative of Theophylline, a scheduled bulk drug, and thus subject to price control. The factual background included a newspaper article highlighting the pharmaceutical industry's shift towards more profitable drugs like Doxofylline, prompting the government to investigate its classification. The Technical Committee of the National Pharmaceutical Pricing Authority (NPPA) sought expert opinions, which confirmed Doxofylline as a derivative of Theophylline. Despite the respondents' claims that Doxofylline was a new drug and not a bulk drug, the court found that it conformed to the definition of a bulk drug under the DPCO, 1995. The court analyzed the definitions within the DPCO and concluded that the appellants had the authority to fix prices based on the information available, despite the manufacturers' non-compliance. Ultimately, the Supreme Court upheld the government's price fixation, affirming the classification of Doxofylline as a bulk drug and allowing for price control under the DPCO, 1995.
Headnote
A) Administrative Law - Price Control - Definition of Bulk Drug - Doxofylline classified as a derivative of Theophylline under Drugs (Prices Control) Order, 1995 - Court held that Doxofylline meets the criteria of a bulk drug as it is a derivative of a scheduled bulk drug, Theophylline, thus enabling price fixation under the DPCO, 1995. (Paras 17-19) B) Administrative Law - Scheduled Formulation - Doxofylline not listed in First Schedule - Court affirmed that Doxofylline formulations cannot be classified as scheduled formulations due to absence from the First Schedule of DPCO, 1995, impacting price control applicability. (Paras 15-16) C) Administrative Law - Compliance with DPCO - Manufacturers' failure to provide necessary information - Court noted that the appellants acted within their authority to fix prices based on available data due to non-compliance by manufacturers. (Paras 6-11)
Issue of Consideration
Whether Doxofylline is a bulk drug and whether the Union of India has the power to fix its price under the DPCO, 1995.
Final Decision
The Supreme Court upheld the price fixation of Doxofylline formulations, affirming that Doxofylline is a bulk drug as it is a derivative of Theophylline, thus allowing the Union of India to fix prices under the DPCO, 1995.
Law Points
- Price fixation
- Bulk drug definition
- Scheduled formulation
- Derivative classification
- DPCO compliance
